Stock Ratings / Health Care / ARTV / dividends

PALI (43) DTIL (24) PLX (28) CGEN (78) ⌘ Pro Terminal →

Artiva Biotherapeutics Inc. (ARTV) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is ARTV trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTV last traded at $4.19 (-0.95% on volume of 1,966,179 shares), positioning the stock -48.34% below its 50-day simple moving average ($8.11) and -47.82% below its 200-day simple moving average ($8.03). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).

Q: Does ARTV pay a dividend and is it safe?

Artiva Biotherapeutics Inc. (ARTV) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$4.19 -0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.17

Artiva Biotherapeutics Inc. (ARTV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $206.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARTV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARTV compare to PALI and DTIL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARTV?

▼

Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.17 (-0.36%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARTV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ARTV SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (38% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 20.6 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.94-15.7% Next Q

Q2 (-2Q)

Grade D$5.85+5.1% Next Q

Q3 (-1Q)

Grade D$6.15-31.9% Next Q

Current

Grade D-$4.19-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARTV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARTV currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.11) and Max Pain ($4.40) forces dealer call-delta covering toward $15.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARTV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARTV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARTV)

✓Walkthrough of ARTV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARTV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.08%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.20H $4.26L $4.10C $4.19VOL 1.97M

RES: $11.55SUP: $3.80SMA50: $8.11SMA200: $8.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARTV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARTV Butterfly Map → + Track ARTV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARTV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARTV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARTV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARTV)

Health Care Rank #553 of 1016 ⚔️ PALI vs ARTV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARTV vs. PALI, DTIL, PLX, CGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artiva Biotherapeutics Inc. (ARTV) ranks #553 by composite RQD confidence (39/100, grade D-) and #572 by equity capitalization ($206.8M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ARTV at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARTV ACTIVE Artiva Biotherapeutics Inc.	D-	39/100	—	—	-35.0%	-0.95%	$206.8M	Benchmark Subject
PALI Palisade Bio Inc.	D-	43/100	—	—	-35.0%	-2.52%	$207.4M	/pali-vs-artv →
DTIL Precision BioSciences Inc.	E	24/100	—	—	-35.0%	-5.11%	$205.4M	/dtil-vs-artv →
PLX Protalix BioTherapeutics Inc.	E	28/100	—	48.8%	-13.0%	-0.77%	$210.3M	/plx-vs-artv →
CGEN Compugen Ltd.	B+	78/100	5.5x	87.3%	85.0%	-2.94%	$193.0M	/cgen-vs-artv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817241

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artiva Biotherapeutics Inc. (ARTV) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $251.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$83.9M, operating cash flow of -$76.8M, and free cash flow of -$79.3M (-42.5% YoY). On the balance sheet, ARTV closed FY2025 with $130.9M in total assets against $0 in total debt (Altman Z-Score: 1.03, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$83.9M	-$76.8M	-$79.3M	$130.9M	—
FY2024 (FY)	2024-12-31	$251.0K	-$65.4M	-$55.0M	-$55.7M	$209.6M	—
FY2023 (FY)	2023-12-31	$32.9M	-$28.7M	-$47.4M	-$47.4M	—	—

3. ARTV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARTV compare to PALI and DTIL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARTV?

Where is ARTV trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTV last traded at $4.19 (-0.95% on volume of 1,966,179 shares), positioning the stock -48.34% below its 50-day simple moving average ($8.11) and -47.82% below its 200-day simple moving average ($8.03). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).

ARTV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ARTV pay a dividend and is it safe?

Artiva Biotherapeutics Inc. (ARTV) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ARTV RQD Cockpit ARTV 12M Forecast ARTV Earnings & Move ARTV Dividends & DRIP ARTV Insiders & 13F ARTV Whale Options ARTV Profit Sankey ARTV News & Why